Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Surgery PartnersFRA:1SP -2.29%65 EBITDA Margin % is 12.86% as of Mar. 2026, which is 24% below its 10-year median of 16.93. GuruFocus rates FRA:1SP with a GF Score™ of 65/100 and a GF Value™ of €23.00 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 662 Healthcare Providers & Services companies, Surgery Partners ranks better than 67.22% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Surgery Partners's EBITDA for the
three
months ended in Mar. 2026 was €90 Mil. Surgery Partners's Revenue for the
three
months ended in Mar. 2026 was €701 Mil. Therefore, Surgery Partners's EBITDA margin for the quarter that ended in Mar. 2026 was 12.86%.
Surgery Partners (FRA:1SP) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Surgery Partners EBITDA Margin % Related Terms
Surgery Partners EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Surgery Partners's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1SP vs AVAH, ASTH, ADUS: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Surgery Partners's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgery Partners EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Surgery Partners's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Surgery Partners's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgery Partners (FRA:1SP) has a EBITDA Margin % of 12.86% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Surgery Partners and its competitors. This is 24% below median its historical median of 16.93. Over the past decade, Surgery Partners' EBITDA Margin % has ranged from 8.20 to 20.28. According to the industry distribution chart, Surgery Partners ranks #217 out of 662 companies in the Healthcare Providers & Services industry, placing it in the top 32.8%.
Is Surgery Partners' EBITDA Margin % too high?
Surgery Partners' current EBITDA Margin % of 12.86% is 24% below median its 10-year median of 16.93. Over the past 10 years, this metric has ranged from a low of 8.20 to a high of 20.28. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. Surgery Partners' value of 12.86% is 25.6% above this industry median. Based on the distribution chart, Surgery Partners ranks #217 out of 662 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Surgery Partners has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Surgery Partners' EBITDA Margin % compare to AVAH and ASTH?
According to the Healthcare Providers & Services industry distribution chart, Surgery Partners ranks #217 out of 662 companies for EBITDA Margin %. This puts Surgery Partners in the upper half of its industry. The industry median EBITDA Margin % is 10.24. Surgery Partners' value of 12.86% is 25.6% above this benchmark. Historically, Surgery Partners' own EBITDA Margin % has ranged from 8.20 to 20.28 over the past decade. While the company's 10-year median is 16.93 vs. the industry median of 10.24, Surgery Partners has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surgery Partners's current EBITDA Margin % of 12.86% is 25.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Surgery Partners and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surgery Partners's current EBITDA Margin % is 12.86%, which is 24% below median its own 10-year median of 16.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgery Partners stock overvalued right now?
Based on GuruFocus' analysis, Surgery Partners (FRA:1SP) is currently considered Possible Value Trap. The stock's GF Value™ is €23.00, compared to a current price of €12.80 — trading 44.3% below its estimated fair value. The current EBITDA Margin % is 12.86%, which is 24% below median its 10-year median of 16.93 and 25.6% above the Healthcare Providers & Services industry median of 10.24. Surgery Partners' overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Surgery Partners (FRA:1SP), the current EBITDA Margin % is 12.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgery Partners (FRA:1SP) Overvalued in 2026?
Based on GuruFocus' analysis, Surgery Partners stock appears to be undervalued.
The current stock price of €12.80 is trading 44.3% below its estimated GF Value™ of €23.00.
GuruFocus considers Surgery Partners to be Possible Value Trap.
Key valuation signals for FRA:1SP:
EBITDA Margin %: 12.86% (24% below median its 10-year median of 16.93)
GF Value™: €23.00 vs. price of €12.80 (44.3% below fair value)
Industry Position: 25.6% above the Healthcare Providers & Services median (#217 of 662)
No single metric tells the full story. See the FRA:1SP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.
65GF Score
Get the complete analysis for FRA:1SP
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1SP has been successfully added to your 
